Halozyme Therapeutics (HALO) EPS (Basic) Growth (3y) (2013 - 2026)
Halozyme Therapeutics (HALO) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 53.55% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 37.73% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.29% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -2.89% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 86.43% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Halozyme Therapeutics | 9.55 Bn | 9.23 Bn | 297.47 Mn | 62.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.98% |
| Dec 31, 2025 | -68.71% |
| Sep 30, 2025 | 49.06% |
| Jun 30, 2025 | 102.28% |
| Mar 31, 2025 | 29.96% |
| Dec 31, 2024 | 31.53% |
| Sep 30, 2024 | -10.86% |
| Jun 30, 2024 | 4.55% |
| Mar 31, 2024 | 44.11% |
| Dec 31, 2023 | 6.41% |
| Sep 30, 2023 | 32.75% |
| Jun 30, 2023 | 44.03% |
| Mar 31, 2023 | 104.84% |
| Dec 31, 2022 | 55.63% |
| Sep 30, 2022 | 66.76% |
| Jun 30, 2022 | 53.76% |
| Mar 31, 2022 | 227.70% |
| Dec 31, 2021 | 224.17% |
| Sep 30, 2021 | 114.60% |
| Jun 30, 2021 | 81.97% |